As a form of immunotherapy, immune checkpoint inhibitors targeting the anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway have been widely explored in cervical cancer. This evidence concerns the gene CD274 and cervical carcinoma.